| BMY |
Report |
Total Revenue (Q2 2026) |
BEAT |
pred ~$12.00B vs. cons $11.74B |
MEDIUM |
| BMY |
Report |
Non-GAAP Diluted EPS (Q2 2026) |
BEAT |
pred ~$1.72 vs. cons $1.60 |
HIGH |
| BMY |
Report |
Eliquis Worldwide Net Revenue (Q2 2026) |
MISS |
pred ~$3.85B vs. cons ~$4.05B |
MEDIUM |
| BMY |
Guide |
FY2026 Total Revenue Guidance |
BETTER |
guide ~$47.0B-$48.5B (mid ~$47.75B) vs. cons ~$47.1B (FY2026) |
MEDIUM |
| BMY |
Guide |
FY2026 Non-GAAP EPS Guidance |
BETTER |
guide ~$6.20-$6.50 (mid ~$6.35) vs. cons $6.32 (FY2026) |
MEDIUM |
| BMY |
Guide |
Eliquis WW Full-Year Growth Commentary |
UNCHANGED |
guide ~10%-15% (reaffirmed) vs. cons ~12% (FY2026) |
MEDIUM |
| BMY |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.5% |
— |
MEDIUM |
| BMY |
Return |
5-day cumulative residual |
+0.5% (FADE) |
BMY enters the print near 52-week highs, up ~19% YTD and trading above the Street's average PT ($62.65 vs $63.67 close), so a beat-and-modest-raise is largely pre-positioned; the FY26 guide raise mainly reflects H1 upside already banked (Q1 beat revenue by $580M) rather than new out-period acceleration, while the Eliquis wholesaler-inventory reversal and looming EU (Nov'26)/US (2027) LOE keep H2 estimate revisions capped. Expect an initial pop on the EPS/revenue beat that partially fades over the week as sell-side models the Eliquis optics miss and discounts the raise as 'catch-up' rather than a step-change in the multi-year growth algebra, with the Iberdomide PDUFA (Aug 17) becoming the next real catalyst. |
MEDIUM |